Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

16 OTHER OPERATIONS Food Additives and Chemical Operations Eisai is a pioneer in the development of applications for vitamin E and has developed an extensive line of vitamin E-enriched nutritional supplements and antioxidants. Our food additives operations also encompass the supply of food preservatives, sweeteners and other additives to food product manufacturers. Our chemical operations emphasize sales of natural and synthetic vitamin E and include sales of raw materials for the manufacture of pharmaceuticals and cosmetics, such as xylitol and lysozyme hydrochloride. In fiscal 2001, we will focus on the launch of new products for the food product, pharmaceutical, cosmetic and health food markets, and on refining marketing procedures and expanding technical services in response to rapid deregulation in key industries. We will also step up long-term efforts to develop innovative new materials. Veterinary and Livestock Product Operations This category focuses on the sale of nutritional supplements and veterinary drugs developed to ensure safer, healthier livestock and better health care for pets. In fiscal 2000, we sought to improve the category’s profitability by creating a more streamlined structure and undertaking intensive marketing efforts. As a consequence, the category returned to profitability. We also applied for approval for two new vaccines—for fish and poultry—a development that bodes well for the future of these operations. We will continue to prioritize profitable businesses in fiscal 2001 and beyond to ensure stable returns. Pharmaceutical Production Systems and Equipment Operations These operations comprise the development and sale of production systems and equipment for pharmaceutical manufacturers that ensure the quality of ampoules for injection and enhance productivity. In the period under review, we focused marketing efforts on the Automatic Inspection Machine (AIM) and the Eisai Inspection System (EIS), both category mainstays, enabling us to maintain stable profit levels. We will continue to promote concentrated and selective business development to ensure profitability. Eisai Annual Report 2001
REINFORCING OUR RELATIONSHIP WITH STAKEHOLDERS We continue to place a high priority on reinforcing our relationship with stakeholders through enhancing communication. We are expanding communication with patients, medical professionals and consumers via our customer hot line service and our internet Web site. We strongly believe in the importance of effective communication and a solid relationship with stakeholders to achieve success in the 21st century. Accordingly, we have appointed a corporate officer to oversee relationship management. Customer Hot Line Our customer hot line in Japan enables patients, medical professionals and consumers to seek advice and information or make suggestions regarding Eisai products and their usage via telephone, fax or e-mail. Opinions and ideas obtained through the hot line are shared throughout the Company and applied to efforts to improve product performance, quality, services and disclosure. The hot line service has been contacted nearly 310,000 times since its establishment in April 1990. During this time, we have increased accessibility by including hot line contact information on product instruction leaflets and introducing toll-free dialing and year round availability. Suggestions from customers contacting the hot line have led to improvements in drug manufacturing procedures and amendments to product instructions. We will continue to seek ways to enhance the hot line to improve communication with customers. Web Site The Eisai Web site offers a wealth of information of interest to patients and medical professionals, as well as shareholders, investors and general consumers. In the area of medical care, we offer extensive, up-to-date information on treatment methods and drugs for dementia, health care, overthe-counter drugs, vitamins and other topics of interest. We also provide timely seasonal information, such as pollen levels. On the corporate side, the Web site includes press releases, a description of our operations and investor relations information. This year, we also included a summary video of our fiscal 2000 results presentation held in May. The Web site also contains an email contact address for users who have questions or suggestions. Ongoing efforts to enhance the content of our Web site will further increase the importance of this crucial communication tool. Eisai Annual Report 2001 17
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15 and 16: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 17: Consumer Health Care Products The c
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

Create successful ePaper yourself

Delete template?

Save as template?